Standardization

One should not assume that a functional module working fine in one cell type will work the same way in even a closely related cell type (Renshaw, 1993). Whereas traditional engineering practices typically rely on the standardization of parts, the uncertain and intricate nature of biology makes standardization in the synthetic biology field difficult. Beyond typical circuit design issues, synthetic biologists must also account for cell death, crosstalk, mutations, intracellular and extracellular conditions, noise and other biological phenomena. As the number of system components grows, it becomes increasingly difficult to coordinate component inputs and outputs to produce the overall desired behaviour (Purnick & Weiss, 2009). In the St²OOL Project, we wanted to check how standard biobricks are. For this goal, we are using a set of strains of Escherichia coli transformed, in single transformation, with ten different Biobricks whose outputs will be measured by fluorometry, colorimetry or luminometry. The aim of this approach is simple and fits with the answer to the following question:

Will the Biobricks behave the same way independently of the host strain they have been transformed into? Will we obtain the same output from all of them? The answer to these questions… in our result section!

Orthogonality

Do biobricks behave independently when cotransformed in a cell? In other words, can we consider them to be orthogonal? Orthogonality is a mathematical concept that refers to the independence of behavior. Translating this concept into the biological realm, two constructions can be considered orthogonal when they only interact at specific and predictable interphases and do not disturb each other. This is a desirable feature of Biobricks if one wants to build synthetic circuits with predictable and robust behaviors.

To study this pillar of synthetic biology we are analyzing different combinations of Biobricks in cotransformed cells. That way, we can study the expression of pairs of Biobricks and compare them with simple transformations, and therefore determine whether the presence of two constructions in the same cell affects their behavior. In order to do so, we will measure the output of each Biobrick (i.e. fluorescense) in both the cotransformants and the controls.

We are going to study three combinations, taking in to account that each pair of biobricks is controlled by the same promoter and only differs in the protein expressed and the antibiotic resistance:

• Constitutive promoter I (strong) – GFP & Constitutive promoter I (strong) – RFP
• Constitutive promoter II (less strong) – GFP & Constitutive promoter I (strong) – RFP
• Ptrc – lacZ & Ptrc – luciferase

Besides individually transformed cells, we will use a control consisting of cotransformed cells with a Biobrick-bearing plasmid and an empty one.

We are currently working on all this. But we have another, very ambitious experiment. We plan to determine the effect of the production of a single heterologous protein on the proteomic architecture of the host cell. For this endeavor, we just submitted our samples for a proteomic quantification.

Open License

We did not want the Human Practices section to be a cosmetic addendum to our iGEM project. In The St²OOL, we have performed a critical but constructive analysis of four of the pillars of the competition. Three of them are technical, engineering assumptions (stability, standardization, orthogonality). The fourth leg of our St²OOL is for us at least as important as the other three, and deals with the answer to this difficult question: who owns synthetic bio-constructions?

iGEM is linked to the Registry of Standard Biological Parts, a non-profit organization (as iGEM Foundation itself) archiving and distributing thousands of BioBrick parts for free (http://parts.igem.org/Main_Page). No patents, no licenses, no royalties. Just Open Access (either totally free access or under certain conditions such as a creative commons subscription). As stated in their Website, it’s “an open community that runs and grows on the Get & Give (& Share) philosophy. Users get parts, samples, data, and tools from the Registry to work on their synthetic biology projects. They will give back to the Registry the new parts they have made, as well as data and experience on new and existing parts”. But of course, the world of Biotechnology/SynBio is far more than iGEM and a range of Intellectual Property protection formulas do exist. Is iGEM an island of Free Access in an ocean of patentable SynBio achievements? How can one deal with the variety of IP forms?

Human Practices Section

The Seat of the St²OOL

By checking how standard, stable, orthogonal or patentable Biobricks are we have performed an analysis of four engineering pillars. But we wanted to combine these pillars, these four legs of our St²OOL, with a truly synthetic and constructive approach.

In The Seat of the St²OOL we are developing a functional metagenomic strategy in which we aim at isolating promoter sequences from natural environments. We will then characterize these sequences in order to select those with the highest stability, standard and orthogonal behaviors. We are working with soil and compost samples, from which we will isolate total metagenomic DNA, which will then be digested, ligated into an expression vector and used to built a library in E. coli. Transformants –clones with a promoter-like natural sequence- will be subjected to a range of stresses and subtransformation steps to find out their stability and standard/orthogonal behavior. To the best of our knowledge, this is the first Synthetic Biology functional metagenomic approach aiming at selecting biological parts not because of their “strength” but because of their compatibility with other parts and suitability for engineering purposes.

Finally, one technical –yet important- detail: we are not using neither commercial kits nor manual protocols for isolating metagenomic DNA. We are building our own robot…

Our robot design